Abstracts tagged "biosimilars and education"

Abstract Number: 2265 • 2019 ACR/ARP Annual Meeting
The Effects of Message Framing on Patients’ Perceptions and Willingness to Switch to a Biosimilar
Chiara Gasteiger ¹, Annie Jones ¹, Maria Kleinstauber ¹, Maria Lobo ², Robert Horne ³, Keith Petrie ¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Auckland District Health Board, Auckland, New Zealand, ³University College London, London, United Kingdom
Background/Purpose: Patients may hold negative perceptions towards biosimilars which can create barriers to their uptake. Physicians also report uncertainty in how best to explain biosimilars.…
Abstract Number: 1040 • 2017 ACR/ARHP Annual Meeting
Perceptions of US Community Rheumatologists on Biosimilars
Janna Radtchenko, Yolaine Smith, Jonathan Kish and Bruce Feinberg, Specialty Solutions, Cardinal Health, Dallas, TX
Background/Purpose: Biosimilars contain a highly similar version of the active substance of an already approved biologic or “reference product.”1 Regulatory agencies mandate that safety, efficacy,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].